Redcare Pharmacy NV
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare P… Read more
Redcare Pharmacy NV (RDC) - Net Assets
Latest net assets as of December 2025: €479.20 Million EUR
Based on the latest financial reports, Redcare Pharmacy NV (RDC) has net assets worth €479.20 Million EUR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.25 Billion) and total liabilities (€767.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €479.20 Million |
| % of Total Assets | 38.44% |
| Annual Growth Rate | 31.4% |
| 5-Year Change | 15.36% |
| 10-Year Change | 413.91% |
| Growth Volatility | 1017.37 |
Redcare Pharmacy NV - Net Assets Trend (2013–2025)
This chart illustrates how Redcare Pharmacy NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Redcare Pharmacy NV (2013–2025)
The table below shows the annual net assets of Redcare Pharmacy NV from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €479.20 Million | -6.03% |
| 2024-12-31 | €509.97 Million | -7.62% |
| 2023-12-31 | €552.03 Million | +55.66% |
| 2022-12-31 | €354.63 Million | -14.63% |
| 2021-12-31 | €415.41 Million | -2.29% |
| 2020-12-31 | €425.14 Million | +82.65% |
| 2019-12-31 | €232.76 Million | +8.78% |
| 2018-12-31 | €213.98 Million | -10.46% |
| 2017-12-31 | €238.97 Million | +156.28% |
| 2016-12-31 | €93.25 Million | +3691.99% |
| 2015-12-31 | €2.46 Million | -87.74% |
| 2014-12-31 | €20.06 Million | +10.93% |
| 2013-12-31 | €18.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Redcare Pharmacy NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35820000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €400.00K | 0.09% |
| Other Comprehensive Income | €61.50 Million | 13.39% |
| Other Components | €755.50 Million | 164.53% |
| Total Equity | €459.20 Million | 100.00% |
Redcare Pharmacy NV Competitors by Market Cap
The table below lists competitors of Redcare Pharmacy NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Changyuan Group Ltd
SHG:600525
|
$587.87 Million |
|
Etablissements Maurel et Prom SA
PA:MAU
|
$587.91 Million |
|
Jiangsu Province Commun
SHG:603018
|
$588.36 Million |
|
Lexinfintech Holdings Ltd
NASDAQ:LX
|
$588.61 Million |
|
BioAge Labs, Inc
NASDAQ:BIOA
|
$587.63 Million |
|
Utz Brands Inc
NYSE:UTZ
|
$587.55 Million |
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
$587.43 Million |
|
Tokyo Steel Manufacturing Co., Ltd.
PINK:TOKSF
|
$587.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Redcare Pharmacy NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 483,981,000 to 459,200,000, a change of -24,781,000 (-5.1%).
- Net loss of 37,700,000 reduced equity.
- Share repurchases of 157,300,000 reduced equity.
- New share issuances of 400,000 increased equity.
- Other comprehensive income increased equity by 8,534,000.
- Other factors increased equity by 161,285,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-37.70 Million | -8.21% |
| Share Repurchases | €157.30 Million | -34.26% |
| Share Issuances | €400.00K | +0.09% |
| Other Comprehensive Income | €8.53 Million | +1.86% |
| Other Changes | €161.28 Million | +35.12% |
| Total Change | €- | -5.12% |
Book Value vs Market Value Analysis
This analysis compares Redcare Pharmacy NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.44x to 1.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €1.99 | €40.74 | x |
| 2014-12-31 | €2.21 | €40.74 | x |
| 2015-12-31 | €0.27 | €40.74 | x |
| 2016-12-31 | €10.28 | €40.74 | x |
| 2017-12-31 | €25.16 | €40.74 | x |
| 2018-12-31 | €17.76 | €40.74 | x |
| 2019-12-31 | €17.82 | €40.74 | x |
| 2020-12-31 | €29.57 | €40.74 | x |
| 2021-12-31 | €23.23 | €40.74 | x |
| 2022-12-31 | €19.72 | €40.74 | x |
| 2023-12-31 | €27.14 | €40.74 | x |
| 2024-12-31 | €24.13 | €40.74 | x |
| 2025-12-31 | €22.84 | €40.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Redcare Pharmacy NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.28%
- • Asset Turnover: 2.36x
- • Equity Multiplier: 2.71x
- Recent ROE (-8.21%) is above the historical average (-45.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -15.66% | -5.12% | 2.15x | 1.42x | €-4.64 Million |
| 2014 | -25.10% | -5.95% | 2.87x | 1.47x | €-7.04 Million |
| 2015 | -428.95% | -8.40% | 2.94x | 17.39x | €-10.79 Million |
| 2016 | -19.78% | -10.40% | 1.47x | 1.29x | €-27.77 Million |
| 2017 | -8.94% | -7.52% | 0.95x | 1.25x | €-45.25 Million |
| 2018 | -15.71% | -6.23% | 1.54x | 1.64x | €-55.01 Million |
| 2019 | -15.58% | -5.17% | 1.64x | 1.84x | €-59.55 Million |
| 2020 | -3.94% | -1.73% | 1.80x | 1.26x | €-59.28 Million |
| 2021 | -17.86% | -7.00% | 1.35x | 1.89x | €-115.73 Million |
| 2022 | -21.89% | -6.45% | 1.65x | 2.06x | €-113.11 Million |
| 2023 | -2.31% | -0.67% | 1.76x | 1.96x | €-64.26 Million |
| 2024 | -9.39% | -1.92% | 2.36x | 2.07x | €-93.86 Million |
| 2025 | -8.21% | -1.28% | 2.36x | 2.71x | €-83.62 Million |
Industry Comparison
This section compares Redcare Pharmacy NV's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $991,285,500
- Average return on equity (ROE) among peers: -356.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Redcare Pharmacy NV (RDC) | €479.20 Million | -15.66% | 1.60x | $587.80 Million |
| YSB Inc. (B1S) | $1.88 Billion | -170.24% | 1.77x | $145.06 Million |
| Rite Aid Corporation (RTA1) | $99.03 Million | -543.74% | 85.12x | $11.16 Million |